Kairos Pharma Ltd.

05/05/2026

remains one of the biggest challenges in medicine.

In a new BioSpace article, John Yu, CEO of , explains why it should be treated as a central scientific priority, not an inevitable outcome.

As therapies advance, diseases adapt, limiting long-term effectiveness. Addressing resistance at its core could help extend treatment durability and improve outcomes.

Read more: https://bit.ly/4tI4vkm

We must treat drug resistance as a central scientific priority rather than an unavoidable complication.

04/15/2026

is proud to be recognized as an Emerald Honoree in the Pinnacle Awards for Healthcare for Innovator of Biotech Solutions.

This recognition reflects ’s commitment to advancing innovative cancer therapies, with a focus on addressing drug resistance and improving treatment durability.

We’re grateful for the recognition and encouraged by the continued progress of our team.

Read more: https://bit.ly/3O8mFMR

03/31/2026

Drug resistance remains one of the biggest challenges in cancer treatment.

's CSO, Neil Bhowmick, shares his perspective in this
Drug Target Review article.

Read more: https://bit.ly/4bN3C2h

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.

03/24/2026

At this year's Deal Flow Discovery Conference, 's Chief Scientific Officer, Neil Bhowmick, discussed the Company’s approach to extending the life of existing cancer therapies.

He shares insights on the potential of ENV105 in castration-resistant , including Phase 2 results showing no Grade 3 or Grade 4 toxicities, as well as early progress in EGFR-driven .

Watch the interview: https://bit.ly/474T25e

In our on-the-ground DealFlow Discovery Conference interview, Dr. Neil Bhowmick, Chief Scientific Officer and President of Kairos Pharma (NYSE American: KAPA...

03/02/2026

announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment.

The nextgeneration, designed panEGFR inhibitor for EGFRmutant significantly expands ’s pipeline Targeting a $16.2 billion market opportunity.

Full press release here: bit.ly/4cSNmij

02/26/2026

announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment.

Under the proposed terms of the agreement, will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell ( ): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.

Read the full release here: bit.ly/4sa6XPt

02/04/2026

On , recognizes the global community working to advance new approaches in the fight against cancer.

Through its innovative programs targeting tumor resistance mechanisms, is focused on developing therapies designed to improve outcomes across cancers such as and .

Together, we continue working toward a future with more effective treatment options for patients worldwide.

02/03/2026

is excited to share that Neil Bhowmick, Ph.D., President and Chief Scientific Officer, will be speaking at The Scientist’s upcoming symposium, Emerging Therapeutic Strategies in Oncology, taking place March 17-18, 2026.

The live, on-demand event will bring together leading experts to explore breakthroughs in , targeted treatments, and next-generation cancer therapies shaping the future of .

Register here: https://bit.ly/49MUdYP

01/20/2026

announces it will participate in the 3rd Annual DealFlow Events Discovery Conference, taking place Jan. 28-29, in Atlantic City, NJ.

's CSO, Neil Bhowmick, will deliver a company presentation and be available for one-on-one investor meetings throughout the conference.

Read the full release here: https://bit.ly/49Gb1PP

12/16/2025

Excited to share that ’s Chief Scientific Officer, Dr. Neil Bhowmick, joined the Citeline In Vivo Podcast to discuss the future of resensitization therapy in .

Neil breaks down how targets CD105 to restore sensitivity in hormone-resistant and highlights Phase 2 data showing more than 13 months of median progression-free survival when combined with standard hormone therapy.

Listen to the full episode to hear how is working to advance options for patients with treatment-resistant cancers here: https://bit.ly/48yIsoo

In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.

12/04/2025

recognizes the ongoing need for innovation in men’s health, especially for those facing advanced and treatment-resistant .

is highlighting interim findings from our Phase 2 study, which has shown encouraging clinical benefit and durable progression-free survival.

Learn more about how is advancing prostate cancer research:

kairospharma.com